What is Polomar Health's earnings per share (EPS)?

Polomar Health (PMHS) reported diluted earnings per share of $-0.39 for fiscal year 2025. This represents a -680.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Polomar Health Financials

PMHS

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Polomar Health (PMHS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PMHS FY2025 2026-06-01

Sales momentum improved, but external financing still carries the business because growth has not yet turned into cash.

FY2025 revenue reached $648K with gross margin at 71.0%, but the improved unit economics still did not make the business self-funding. Inventory and receivables totaled $191K, above cash of $132K, and operating cash flow remained negative, so growth is tying up liquidity rather than releasing it.

The balance sheet moved from positive equity in FY2024 to negative equity of -$1.22M in FY2025, while the current ratio was only 0.2x. That means the $132K cash balance sits inside a much tighter short-term funding position than a cash-only glance suggests.

Cash generation still depends on outside financing: FY2025 financing cash flow was $522K while free cash flow was -$487K. In practice, the operating platform has not yet begun to fund its own working-capital needs or fixed charges.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Polomar Health's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

100

Polomar Health's revenue surged 1002.0% year-over-year to $648K, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Polomar Health carries a low D/E ratio of -1.32, meaning only $-1.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Polomar Health's current ratio of 0.20 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

3/9

Polomar Health passes 3 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$648K

YoY+1002.0%

Polomar Health generated $648K in revenue in fiscal year 2025. This represents an increase of 1002.0% from the prior year.

EBITDA

-$777K

YoY+25.0%

Polomar Health's EBITDA was -$777K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.0% from the prior year.

Net Income

N/A

EPS (Diluted)

$-0.39

YoY-680.0%

Polomar Health earned $-0.39 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 680.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$132K

YoY+2034.6%

Polomar Health held $132K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

28M

YoY+1.4%

Polomar Health had 28M shares outstanding in fiscal year 2025. This represents an increase of 1.4% from the prior year.

Margins & Returns

Gross Margin

71.0%

YoY+18.4pp

Polomar Health's gross margin was 71.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 18.4 percentage points from the prior year.

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

PMHS Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	$648K+1002.0%	$59K+40.6%	$42K+21.2%	$35K
Cost of Revenue	$188K+573.8%	$28K+550.2%	$4K	N/A
Gross Profit	$460K+1388.8%	$31K-17.7%	$38K+8.8%	$35K
R&D Expenses	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$1.3M+185.1%	$450K+108.6%	$216K
Operating Income	N/A	-$1.3M-194.8%	-$441K-142.9%	-$181K
Interest Expense	$151K+260.5%	$42K+8351.9%	$495	N/A
Income Tax	N/A	N/A	N/A	N/A
Net Income	N/A	-$1.3M	N/A	-$181K
EPS (Diluted)	$-0.39-680.0%	$-0.05-150.0%	$-0.02	$0.00

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$1.0M+59.1%	$632K+10155.7%	$6K+12.7%	$5K+20.4%	$5K	N/A	$10K	N/A
Cost of Revenue	$455K+148.3%	$183K+9861.6%	$2K+12.3%	$2K+20.4%	$1K	N/A	$985	N/A
Gross Profit	$550K+22.7%	$449K+10280.8%	$4K+12.8%	$4K+20.4%	$3K	N/A	$9K	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$246K	N/A	$619K+11.2%	$557K+39.6%	$399K	N/A	$256K	N/A
Operating Income	-$7K	N/A	-$629K-11.6%	-$563K-35.6%	-$415K	N/A	-$259K	N/A
Interest Expense	$18K-60.0%	$46K+120.3%	$21K-50.4%	$42K+1.9%	$41K	N/A	$12K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$25K	N/A	-$650K-7.3%	-$606K-32.6%	-$457K+36.4%	-$719K-164.9%	-$271K	N/A
EPS (Diluted)	$0.00	N/A	$-0.020.0%	$-0.020.0%	$-0.02	N/A	$-0.01	$-0.01

PMHS Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$390K-96.1%	$10.0M+9192.1%	$107K-59.0%	$261K
Current Assets	$323K+320.1%	$77K+526.2%	$12K-95.3%	$261K
Cash & Equivalents	$132K+2034.6%	$6K+2663.8%	$224-99.9%	$226K
Inventory	$94K+36.1%	$69K+1888.3%	$3K	N/A
Accounts Receivable	$97K+5154.3%	$2K	N/A	$30K
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M+19.2%	$1.4M+792.0%	$152K+103.0%	$75K
Current Liabilities	$1.6M+20.5%	$1.3M+1205.7%	$102K+37.1%	$75K
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	-$1.2M-114.2%	$8.6M+19408.3%	-$45K-123.8%	$187K
Retained Earnings	-$13.6M-367.6%	-$2.9M-85.4%	-$1.6M-59.9%	-$982K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$517K+32.4%	$390K-95.8%	$9.3M-1.7%	$9.4M-3.8%	$9.8M-1.4%	$10.0M-3.3%	$10.3M+3501704.1%	$294
Current Assets	$468K+44.9%	$323K+63.3%	$198K+112.4%	$93K-53.8%	$201K+161.9%	$77K-50.8%	$156K+52996.9%	$294
Cash & Equivalents	$88K-33.5%	$132K+240.1%	$39K+730.6%	$5K-96.4%	$129K+1989.0%	$6K-61.8%	$16K+5410.9%	$294
Inventory	$209K+123.2%	$94K-41.0%	$159K+113.5%	$74K+6.2%	$70K+1.8%	$69K-50.8%	$140K	N/A
Accounts Receivable	$171K+76.2%	$97K	N/A	$2K0.0%	$2K0.0%	$2K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$250K	N/A
Total Liabilities	$1.8M+9.3%	$1.6M+7.3%	$1.5M+45.0%	$1.0M-37.8%	$1.7M+23.2%	$1.4M+38.4%	$977K+146.8%	$396K
Current Liabilities	$1.8M+9.3%	$1.6M+7.3%	$1.5M+45.0%	$1.0M-37.5%	$1.7M+24.1%	$1.3M+40.3%	$954K+826.2%	$103K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.2M-1.9%	-$1.2M-115.7%	$7.8M-7.5%	$8.4M+3.1%	$8.1M-5.3%	$8.6M-7.7%	$9.3M+2454.5%	-$396K
Retained Earnings	-$13.6M-0.2%	-$13.6M-194.4%	-$4.6M-16.4%	-$4.0M-18.0%	-$3.4M-15.7%	-$2.9M-32.8%	-$2.2M-47.4%	-$1.5M

PMHS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$396K+61.2%	-$1.0M-90.9%	-$534K-1205.3%	-$41K
Capital Expenditures	N/A	$91K	N/A	N/A
Free Cash Flow	N/A	-$1.1M	N/A	N/A
Investing Cash Flow	N/A	-$91K	N/A	N/A
Financing Cash Flow	$522K-52.9%	$1.1M+249.0%	$317K+19.1%	$267K
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$34K-81.9%	$190K+153.9%	-$353K-87.8%	-$188K-312.0%	-$46K+85.5%	-$315K-7.8%	-$292K	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$11K	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$315K-4.0%	-$303K	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0+100.0%	-$11K	N/A
Financing Cash Flow	-$79K+18.6%	-$97K-125.0%	$387K+512.8%	$63K-62.6%	$169K-44.7%	$305K+2.0%	$299K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PMHS Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	71.0%+18.4pp	52.5%-37.2pp	89.7%-10.3pp	100.0%
Operating Margin	N/A	-2209.1%-1155.6pp	-1053.5%-528.0pp	-525.5%
Net Margin	N/A	-2280.3%	N/A	-524.6%
Return on Equity	N/A	-15.6%	N/A	-97.0%
Return on Assets	N/A	-13.5%	N/A	-69.3%
Current Ratio	0.20+0.1	0.06-0.1	0.12-3.4	3.50
Debt-to-Equity	-1.32-1.5	0.16+3.6	-3.40-3.8	0.40
FCF Margin	N/A	-1888.1%	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	54.8%-16.2pp	71.0%+0.9pp	70.1%+0.1pp	70.0%0.0pp	70.1%	N/A	90.0%	N/A
Operating Margin	-0.7%	N/A	-10203.0%+95.6pp	-10298.6%-1152.7pp	-9145.9%	N/A	-2631.5%	N/A
Net Margin	-2.5%	N/A	-10543.2%+527.5pp	-11070.6%-1012.2pp	-10058.5%	N/A	-2754.9%	N/A
Return on Equity	N/A	N/A	-8.4%-1.2pp	-7.2%-1.6pp	-5.6%+2.7pp	-8.4%-5.4pp	-2.9%	N/A
Return on Assets	-4.9%	N/A	-7.0%-0.6pp	-6.4%-1.8pp	-4.7%+2.6pp	-7.2%-4.6pp	-2.6%	N/A
Current Ratio	0.27+0.1	0.20+0.1	0.13+0.0	0.09-0.0	0.12+0.1	0.06-0.1	0.16+0.2	0.00
Debt-to-Equity	-1.41-0.1	-1.32-1.5	0.19+0.1	0.12-0.1	0.20+0.0	0.16+0.1	0.10+1.1	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-3074.2%	N/A

Note: Shareholder equity is negative (-$1.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.20), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Polomar Health's annual revenue?

Polomar Health (PMHS) reported $648K in total revenue for fiscal year 2025. This represents a 1002.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Polomar Health's revenue growing?

Polomar Health (PMHS) revenue grew by 1002% year-over-year, from $59K to $648K in fiscal year 2025.

What is Polomar Health's EBITDA?

Polomar Health (PMHS) had EBITDA of -$777K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Polomar Health's gross margin?

Polomar Health (PMHS) had a gross margin of 71.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Polomar Health's operating cash flow?

Polomar Health (PMHS) generated -$396K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Polomar Health's total assets?

Polomar Health (PMHS) had $390K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Polomar Health have outstanding?

Polomar Health (PMHS) had 28M shares outstanding as of fiscal year 2025.

What is Polomar Health's current ratio?

Polomar Health (PMHS) had a current ratio of 0.20 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Polomar Health's debt-to-equity ratio?

Polomar Health (PMHS) had a debt-to-equity ratio of -1.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Polomar Health's cash runway?

Based on fiscal year 2025 data, Polomar Health (PMHS) had $132K in cash against an annual operating cash burn of $396K. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Polomar Health's debt-to-equity ratio negative or unusual?

Polomar Health (PMHS) has negative shareholder equity of -$1.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Polomar Health's Piotroski F-Score?

Polomar Health (PMHS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

How financially healthy is Polomar Health?

Polomar Health (PMHS) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.